Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Freemantle

Showing results (21-30 of 174) with videos related to

Pageof 18
Sort By:
BMJ (Clinical Research Ed.)|March 6, 1993
NHS reformsI Watt, N Freemantle
BMJ (Clinical Research Ed.)|May 5, 1998
Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawedN Freemantle, J Mason
Health Libraries Review|May 8, 1994
Dissemination: implementing the findings of researchN Freemantle, I Watt
Pharmacoeconomics|June 6, 1997
Publication bias in clinical trials and economic analysesN Freemantle, J Mason
Pharmacoeconomics|August 18, 2000
The importance of achieving additional drug benefits at a reasonable cost. A review of the fluoxetine yearsN Freemantle, J Mason
The Health Service Journal|June 8, 1992
Infant science, adult problemN Freemantle, C Pollock
Journal of Clinical Pharmacy and Therapeutics|October 18, 2002
Using effectiveness studies for prescribing research, part 1N Freemantle, J Eastaugh
BMJ (Clinical Research Ed.)|May 7, 1999
Cluster randomised trials. Standardised approach to analysing and reporting these trials is misguidedN Freemantle, J Wood
Pharmacoeconomics|May 7, 1998
The dilemma of new drugs. Are costs rising faster than effectiveness?J Mason, N Freemantle
The Health Service Journal|October 22, 1993
Short measuresT Sheldon, N Freemantle
Pageof 18

Showing results (21-30 of 174) with videos related to

Sort By:
Pageof 18
BMJ (Clinical Research Ed.)|March 6, 1993
NHS reformsI Watt, N Freemantle
BMJ (Clinical Research Ed.)|May 5, 1998
Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawedN Freemantle, J Mason
Health Libraries Review|May 8, 1994
Dissemination: implementing the findings of researchN Freemantle, I Watt
Pharmacoeconomics|June 6, 1997
Publication bias in clinical trials and economic analysesN Freemantle, J Mason
Pharmacoeconomics|August 18, 2000
The importance of achieving additional drug benefits at a reasonable cost. A review of the fluoxetine yearsN Freemantle, J Mason
The Health Service Journal|June 8, 1992
Infant science, adult problemN Freemantle, C Pollock
Journal of Clinical Pharmacy and Therapeutics|October 18, 2002
Using effectiveness studies for prescribing research, part 1N Freemantle, J Eastaugh
BMJ (Clinical Research Ed.)|May 7, 1999
Cluster randomised trials. Standardised approach to analysing and reporting these trials is misguidedN Freemantle, J Wood
Pharmacoeconomics|May 7, 1998
The dilemma of new drugs. Are costs rising faster than effectiveness?J Mason, N Freemantle
The Health Service Journal|October 22, 1993
Short measuresT Sheldon, N Freemantle
Pageof 18